Ikena Oncology Files 2023 Annual Report on Form 10-K

Ticker: IMA · Form: 10-K · Filed: Mar 12, 2024 · CIK: 1835579

Ikena Oncology, INC. 10-K Filing Summary
FieldDetail
CompanyIkena Oncology, INC. (IMA)
Form Type10-K
Filed DateMar 12, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Ikena Oncology, Biotechnology, Financial Report, SEC Filing

TL;DR

<b>Ikena Oncology, Inc. has filed its 2023 10-K report detailing its business operations, financial status, and key agreements.</b>

AI Summary

Ikena Oncology, Inc. (IMA) filed a Annual Report (10-K) with the SEC on March 12, 2024. Ikena Oncology, Inc. filed its 2023 Form 10-K on March 12, 2024. The company is incorporated in Delaware and operates in the Biological Products sector. Key agreements mentioned include those with the University of Texas at Austin and Bristol Myers Squibb. The filing references various financial instruments and equity types, including common stock and preferred stock. Significant dates include the fiscal year end of December 31, 2023, and past agreements dating back to 2018.

Why It Matters

For investors and stakeholders tracking Ikena Oncology, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Ikena Oncology's financial health and strategic partnerships for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. The detailed information on agreements with entities like Bristol Myers Squibb and the University of Texas at Austin is vital for understanding the company's R&D pipeline and potential revenue streams.

Risk Assessment

Risk Level: medium — Ikena Oncology, Inc. shows moderate risk based on this filing. The company operates in the highly competitive and regulated biotechnology sector, with significant R&D expenses and reliance on successful drug development, as indicated by the numerous references to research, development, and specific agreements.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's current financial position and the inherent risks in drug development.

Key Numbers

Key Players & Entities

FAQ

When did Ikena Oncology, Inc. file this 10-K?

Ikena Oncology, Inc. filed this Annual Report (10-K) with the SEC on March 12, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Ikena Oncology, Inc. (IMA).

Where can I read the original 10-K filing from Ikena Oncology, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Ikena Oncology, Inc..

What are the key takeaways from Ikena Oncology, Inc.'s 10-K?

Ikena Oncology, Inc. filed this 10-K on March 12, 2024. Key takeaways: Ikena Oncology, Inc. filed its 2023 Form 10-K on March 12, 2024.. The company is incorporated in Delaware and operates in the Biological Products sector.. Key agreements mentioned include those with the University of Texas at Austin and Bristol Myers Squibb..

Is Ikena Oncology, Inc. a risky investment based on this filing?

Based on this 10-K, Ikena Oncology, Inc. presents a moderate-risk profile. The company operates in the highly competitive and regulated biotechnology sector, with significant R&D expenses and reliance on successful drug development, as indicated by the numerous references to research, development, and specific agreements.

What should investors do after reading Ikena Oncology, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's current financial position and the inherent risks in drug development. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,404 words · 18 min read · ~15 pages · Grade level 17.4 · Accepted 2024-03-12 07:30:33

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 49 Item 1B. Unresolved Staff Comments 94 Item 1C. Cybersecurity 94 Item 2.

Properties

Properties 95 Item 3.

Legal Proceedings

Legal Proceedings 96 Item 4. Mine Safety Disclosures 96 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 97 Item 6. Reserved 97 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 98 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 107 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 107 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 107 Item 9A.

Controls and Procedures

Controls and Procedures 107 Item 9B. Other Information 108 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 108 PART III Item 10. Directors, Executive Officers and Corporate Governance 109 Item 11.

Executive Compensation

Executive Compensation 109 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 109 Item 13. Certain Relationships and Related Transactions, and Director Independence 109 Item 14. Principal Accounting Fees and Services 109 PART IV Item 15. Exhibits, Financial Statement Schedules 110 Item 16. Form 10-K Summary 112 i Summary of the Material and Other Risks Associated with Our Business Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following: We are a targeted oncology company with a limited operating history. We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale and have not generated any revenue from product sales. We will require additional capital to finance our operations, which may not be available on acceptable terms, or at all. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. We have never successfully completed any clinical trials for our target oncology programs, and we may be unable to do so for any of our current product candidates. Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products. Clinical product development involves a lengthy and expensive process, with an uncer

Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about

Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about: the initiation, timing, progress, results, and cost of our research and development programs and our current and future nonclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; our ability and the potential to successfully manufacture our drug substances and product candidates for preclinical use, for clinical trials, and on a larger scale, for commercial use, if approved; the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates; our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; our ability to commercialize our products, if approved; the pricing and reimbursement of our product candidates, if approved; the implementation of our business model, and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates; estimates of our future expenses, revenue, capital requirements, and our needs for additional financing; the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; future agreements with third parties in connection with the commercialization of product candidates and any other approved product; the size and growth potential of

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing